AnaptysBio Inc logo

ANAB - AnaptysBio Inc Share Price

$26.1 0.1  0.5%

Last Trade - 14/05/21

Mid Cap
Market Cap £506.8m
Enterprise Value £236.9m
Revenue £50.5m
Position in Universe 3180th / 6846
Unlock ANAB Revenue
Relative Strength (%)
1m +24.4%
Volume Change (%)
10d / 3m
Price vs... (%)
52w High -27.2%
50d MA
200d MA
Growth & Value
12m Forecast Rolling Industry Market
Valuation (ttm) Industry Market
Margin of Safety
Qualifying GuruScreens
Financial Summary
Year End 31st Dec 2015 2016 2017 2018 2019 2020 2021E 2022E CAGR / Avg
17.6 16.7 10.00 5.00 8.00 75.0 64.0 70.4 +33.7%
Balance Sheet
FINANCIAL BRIEF: : For the three months ended 31 March 2021, AnaptysBioInc revenues decreased 25% to $11.2M. Net loss increasedfrom $8.3M to $18.2M. Revenues reflect a decrease in demandfor the Company's products and services due to unfavorablemarket conditions. Higher net loss reflects Research anddevelopment - Balancing increase of 16% to $23M (expense),Interest income decrease of 90% to $195K (income).
Health Trend(F-Score)
0 1 2 3 4 5 6 7 8 9
Bankruptcy Score(Z-Score)
Earnings Manipulation Risk(M-Score)
Other Ratios
Recent History
Latest interim period vs. prior period Industry Market
3yr Compound Annual Growth Rate Industry Market
Graphical History


ANAB Revenue Unlock ANAB Revenue

Net Income

ANAB Net Income Unlock ANAB Revenue

Normalised EPS

ANAB Normalised EPS Unlock ANAB Revenue

PE Ratio Range

ANAB PE Ratio Range Unlock ANAB Revenue

Dividend Yield Range

ANAB Dividend Yield Range Unlock ANAB Revenue
Analyst Forecasts
Price Target:
( below Price)
31st Dec 2021
31st Dec 2022
Est. Long Term Growth Rate: Net Profit
Net Profit
Consensus Estimate
1m Change
3m Change
Analyst Consensus
Strong Sell Sell Hold Buy Strong Buy
EPS 2020 /  2021
ANAB EPS Forecasts Unlock ANAB Revenue
Profile Summary

AnaptysBio, Inc. is a clinical-stage biotechnology company. The Company is engaged in developing antibody product candidates focused on unmet medical needs in inflammation and immuno-oncology. The Company develops its product candidates using its antibody discovery technology platform, which is designed to replicate, in vitro, the natural process of antibody generation. Its product pipeline includes ANB020 and ANB019, which are being developed to treat severe inflammatory disorders with unmet medical need. The Company's ANB020 product candidate is an antibody that inhibits the activity of interleukin-33, and is used for the treatment of severe adult asthma and severe adult peanut allergy. In addition, the Company is engaged in developing its ANB019 product candidate, an antibody that inhibits the interleukin-36 receptor, for the treatment of rare inflammatory diseases called generalized pustular psoriasis (GPP) and palmoplantar pustular psoriasis (PPP).

Last Annual December 31st, 2020
Last Interim March 31st, 2021
Incorporated November 16, 2005
Public Since January 26, 2017
No. of Shareholders: 13
No. of Employees: 94
Sector Healthcare
Industry Biotechnology & Medical Research
Index Nasdaq Composite ,
Exchange NASDAQ Global Select Market
Shares in Issue 27,369,199
Free Float (0.0%)
Eligible for
ANAB Share Price Performance
Share Price
Bid - Ask
Low - High
Day's Change
Avg Volume
Open - Close
Range (12m)
Latest News for ANAB
Upcoming Events for ANAB
Thursday 17th June, 2021
AnaptysBio Inc Annual Shareholders Meeting
Friday 18th June, 2021 Estimate
AnaptysBio Inc Annual Shareholders Meeting
Monday 9th August, 2021 Estimate
Q2 2021 AnaptysBio Inc Earnings Release
Tuesday 2nd November, 2021 Estimate
Q3 2021 AnaptysBio Inc Earnings Release
Frequently Asked Questions for AnaptysBio Inc
What is the AnaptysBio Inc share price?

As of 14/05/21, shares in AnaptysBio Inc are trading at $26.1, giving the company a market capitalisation of £506.8m. This share price information is delayed by 15 minutes.

How has the AnaptysBio Inc share price performed this year?

Shares in AnaptysBio Inc are currently trading at $26.1 and the price has moved by 44.44% over the past 365 days. In terms of relative price strength - which takes into account the overall market trend - the AnaptysBio Inc price has moved by 0.58% over the past year.

What are the analyst and broker recommendations for AnaptysBio Inc?

Of the analysts with advisory recommendations for AnaptysBio Inc, there are there are currently 1 "buy" , 2 "hold" and 0 "sell" recommendations. The overall consensus recommendation for AnaptysBio Inc is Hold. You can view the full broker recommendation list by unlocking its StockReport.

When will AnaptysBio Inc next release its financial results?

AnaptysBio Inc is scheduled to issue upcoming financial results on the following dates:

Interim results are scheduled for: 2022-03-31
What is the AnaptysBio Inc dividend yield?

AnaptysBio Inc does not currently pay a dividend.

Does AnaptysBio Inc pay a dividend?

AnaptysBio Inc does not currently pay a dividend.

When does AnaptysBio Inc next pay dividends?

AnaptysBio Inc does not currently pay a dividend.

How do I buy AnaptysBio Inc shares?

To buy shares in AnaptysBio Inc you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.

What is the market cap of AnaptysBio Inc?

Shares in AnaptysBio Inc are currently trading at $26.1, giving the company a market capitalisation of £506.8m.

Where are AnaptysBio Inc shares listed? Where are AnaptysBio Inc shares listed?

Here are the trading details for AnaptysBio Inc:

Country of listing: United States
Exchange: NSQ
Ticker Symbol: ANAB
What kind of share is AnaptysBio Inc?

Based on an overall assessment of its quality, value and momentum, AnaptysBio Inc is currently classified as a Falling Star. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.

Is there a AnaptysBio Inc share price forecast 2021?

Shares in AnaptysBio Inc are currently priced at $26.1. At that level they are trading at 24.52% discount to the analyst consensus target price of 0.00.

Analysts covering AnaptysBio Inc currently have a consensus Earnings Per Share (EPS) forecast of -2.642 for the next financial year.

How can I tell whether the AnaptysBio Inc share price will go up?

An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like AnaptysBio Inc. Over the past six months, the relative strength of its shares against the market has been -21.31%. At the current price of $26.1, shares in AnaptysBio Inc are trading at 14.85% against their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.

What is the AnaptysBio Inc PE Ratio?

We were not able to find PE ratio data for AnaptysBio Inc.

Who are the key directors of AnaptysBio Inc?

AnaptysBio Inc's management team is headed by:

James Topper - CHM
Hamza Suria - PRE
Hollings Renton - LED
Dennis Fenton - IND
Eric Loumeau - COO
Laura Hamill - IND
Dennis Mulroy - CFO
Paul Lizzul - OTH
Magda Marquet - DRC
Oleg Nodelman - DRC
Who are the major shareholders of AnaptysBio Inc?

Here are the top five shareholders of AnaptysBio Inc based on the size of their shareholding:

EcoR1 Capital, LLC Hedge Fund
Percentage owned: 27.48% (7.52m shares)
Tang Capital Management, LLC Hedge Fund
Percentage owned: 9.6% (2.63m shares)
The Vanguard Group, Inc. Investment Advisor/Hedge Fund
Percentage owned: 8.49% (2.32m shares)
BlackRock Institutional Trust Company, N.A. Investment Advisor
Percentage owned: 6.31% (1.73m shares)
Perceptive Advisors LLC Private Equity
Percentage owned: 5.46% (1.50m shares)
Similar to ANAB
© Stockopedia 2021, Refinitiv, Share Data Services.
This site cannot substitute for professional investment advice or independent factual verification. To use it, you must accept our Terms of Use, Privacy and Disclaimer policies.